ImmunoBrain to Present Phase 1b Data for Alzheimer’s Therapy IBC-Ab002 at AD/PD 2026

New approaches to treating neurodegenerative diseases are increasingly focusing on the role of the immune system in brain health.

Clinical-stage biotech company ImmunoBrain has announced that new Phase 1b clinical data for its investigational therapy IBC-Ab002 will be presented at the upcoming Alzheimer's and Parkinson's Diseases Conference 2026.

The conference will take place March 17–21, 2026, in Copenhagen, Denmark.

A Novel Immunotherapy Approach for Alzheimer’s Disease

IBC-Ab002 is an engineered antibody designed to target the PD-L1 immune checkpoint pathway, which plays a role in regulating immune responses.

The therapy has been specifically developed for treating neurodegenerative disorders such as:

• Alzheimer's Disease
• Other progressive neurological conditions

Unlike conventional treatments that focus mainly on amyloid or tau proteins, ImmunoBrain’s strategy aims to activate the peripheral immune system to help protect and repair the brain.

The investigational drug is a Fc-modified anti-PD-L1 monoclonal antibody designed for intermittent dosing and transient immune checkpoint blockade.

Phase 1b Study Overview

The upcoming presentation will highlight topline results from the Phase 1b IBC-01-01 study.

The study evaluated:

• Safety and tolerability
• Biomarker responses
• Dose escalation effects

A total of 40 patients with early Alzheimer’s disease participated in the trial.

Key study characteristics include:

• Four intravenous infusions of IBC-Ab002 or placebo
• Five escalating dose cohorts
• Monitoring of clinical and biomarker outcomes

These findings represent an important early step in understanding the therapy’s potential in neurodegenerative disease treatment.

Conference Presentation Details

The study results will be presented during a scientific session at the Alzheimer's and Parkinson's Diseases Conference 2026.

Presentation details:

• Session: Mechanistic Modifiers of AD: APOE, Immunity, and Neural Circuits
• Title: PD-L1 Immune Checkpoint Blockade in Early Alzheimer’s Disease: Topline Results from the Phase 1b IBC-01-01 Study
• Date: March 19, 2026
• Time: 8:55 a.m. CET
• Location: Hall 180-181
• Presenter: Catherine J. Mummery

The Science Behind ImmunoBrain’s Strategy

ImmunoBrain is developing therapies based on a neuro-immunology concept that links immune system activity to brain repair.

This approach builds on more than 25 years of research led by the company’s scientific co-founder, Michal Schwartz, at the Weizmann Institute of Science.

Their work demonstrated that:

• The brain relies on a healthy immune system for maintenance and repair
• Immune responses can support neuroprotection and recovery in degenerative conditions

These insights have led to the development of immune-modulating therapies aimed at restoring protective brain-immune interactions.

Research Support and Collaboration

The Phase 1b study for IBC-Ab002 was supported in part by funding from:

• National Institute on Aging
• Alzheimer's Association

The trial is registered under ClinicalTrials.gov identifier NCT05551741.

Important Note on Early-Stage Research

The company emphasized that the findings represent early-stage clinical research.

Results presented at the conference are preliminary and intended for scientific discussion.
Further studies will be required to evaluate the therapy’s safety, effectiveness, and regulatory potential.

The Bigger Picture

With global cases of Alzheimer's Disease continuing to rise, researchers are exploring new biological pathways beyond traditional targets.

Immune-based therapies like IBC-Ab002 highlight a growing effort to leverage the body’s own defense system to protect the brain.

If successful in later trials, this approach could open new avenues for treating neurodegenerative diseases that currently have limited therapeutic options.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!